Profiles of Overall Survival-related Gene Expression-based Risk Signature and Their Prognostic Implications in Clear Cell Renal Cell Carcinoma

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2020 Aug 14

PMID 32789468

Citations 2

Authors

Zihao He

Tuo Deng

Xiaolu Duan

Guohua Zeng

Affiliations

Soon will be listed here.

Abstract

The present work aimed to evaluate the prognostic value of overall survival (OS)-related genes in clear cell renal cell carcinoma (ccRCC) and to develop a nomogram for clinical use. Transcriptome data from The Cancer Genome Atlas (TCGA) were collected to screen differentially expressed genes (DEGs) between ccRCC patients with OS > 5 years (149 patients) and those with <1 year (52 patients). In TCGA training set (265 patients), seven DEGs (cytochrome P450 family 3 subfamily A member 7 (CYP3A7), contactin-associated protein family member 5 (CNTNAP5), adenylate cyclase 2 (ADCY2), TOX high mobility group box family member 3 (TOX3), plasminogen (PLG), enamelin (ENAM), and collagen type VII α 1 chain (COL7A1)) were further selected to build a prognostic risk signature by the least absolute shrinkage and selection operator (LASSO) Cox regression model. Survival analysis confirmed that the OS in the high-risk group was dramatically shorter than their low-risk counterparts. Next, univariate and multivariate Cox regression revealed the seven genes-based risk score, age, and Tumor, lymph Node, and Metastasis staging system (TNM) stage were independent prognostic factors to OS, based on which a novel nomogram was constructed and validated in both TCGA validation set (265 patients) and the International Cancer Genome Consortium cohort (ICGC, 84 patients). A decent predictive performance of the nomogram was observed, the C-indices and corresponding 95% confidence intervals of TCGA training set, validation set, and ICGC cohort were 0.78 (0.74-0.82), 0.75 (0.70-0.80), and 0.70 (0.60-0.80), respectively. Moreover, the calibration plots of 3- and 5 years survival probability indicated favorable curve-fitting performance in the above three groups. In conclusion, the proposed seven genes signature-based nomogram is a promising and robust tool for predicting the OS of ccRCC, which may help tailor individualized therapeutic strategies.

Citing Articles

Inflammatory response-based prognostication and personalized therapy decisions in clear cell renal cell cancer to aid precision oncology.

Zhong W, Chen H, Yang J, Huang C, Lin Y, Huang J BMC Med Genomics. 2023; 16(1):265.

PMID: 37885006 PMC: 10601329. DOI: 10.1186/s12920-023-01687-5.

Collagen Remodeling along Cancer Progression Providing a Novel Opportunity for Cancer Diagnosis and Treatment.

Song K, Yu Z, Zu X, Li G, Hu Z, Xue Y Int J Mol Sci. 2022; 23(18).

PMID: 36142424 PMC: 9502421. DOI: 10.3390/ijms231810509.

References

Ha M, Son Y, Kim J, Park S, Hong C, Choi D . TEK is a novel prognostic marker for clear cell renal cell carcinoma. Eur Rev Med Pharmacol Sci. 2019; 23(4):1451-1458. DOI: 10.26355/eurrev_201902_17102. View

Pencina M, DAgostino R . Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004; 23(13):2109-23. DOI: 10.1002/sim.1802. View

Kita Y, Mimori K, Tanaka F, Matsumoto T, Haraguchi N, Ishikawa K . Clinical significance of LAMB3 and COL7A1 mRNA in esophageal squamous cell carcinoma. Eur J Surg Oncol. 2008; 35(1):52-8. DOI: 10.1016/j.ejso.2008.01.025. View

Fontanarosa J, Dai Y . Using LASSO regression to detect predictive aggregate effects in genetic studies. BMC Proc. 2012; 5 Suppl 9:S69. PMC: 3287908. DOI: 10.1186/1753-6561-5-S9-S69. View

Gupta K, Miller J, Li J, Russell M, Charbonneau C . Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008; 34(3):193-205. DOI: 10.1016/j.ctrv.2007.12.001. View

Pan Q, Wang L, Zhang H, Liang C, Li B . Identification of a 5-Gene Signature Predicting Progression and Prognosis of Clear Cell Renal Cell Carcinoma. Med Sci Monit. 2019; 25:4401-4413. PMC: 6587650. DOI: 10.12659/MSM.917399. View

Chen Y, Jiang S, Lu Z, Xue D, Xia L, Lu J . Development and verification of a nomogram for prediction of recurrence-free survival in clear cell renal cell carcinoma. J Cell Mol Med. 2019; 24(2):1245-1255. PMC: 6991630. DOI: 10.1111/jcmm.14748. View

Sun M, Marconi L, Eisen T, Escudier B, Giles R, Haas N . Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. Eur Urol. 2018; 74(5):611-620. PMC: 7515772. DOI: 10.1016/j.eururo.2018.05.002. View

Yu H, Yan H, Wang L, Li J, Tan L, Deng W . Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study. Lancet Psychiatry. 2018; 5(4):327-338. DOI: 10.1016/S2215-0366(18)30049-X. View

10.

Qu L, Wang Z, Chen Q, Li Y, He H, Hsieh J . Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Eur Urol. 2018; 74(6):756-763. DOI: 10.1016/j.eururo.2018.07.032. View

11.

Martins V, Vyas J, Chen M, Purdie K, Mein C, South A . Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J Cell Sci. 2009; 122(Pt 11):1788-99. PMC: 2684833. DOI: 10.1242/jcs.042895. View

12.

Zeng M, Qiu J, Xu Y, Zhang X . IDUA, NDST1, SAP30L, CRYBA4, and SI as novel prognostic signatures clear cell renal cell carcinoma. J Cell Physiol. 2019; 234(9):16320-16327. DOI: 10.1002/jcp.28297. View

13.

Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiuchi S . Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res. 1999; 59(19):4990-6. View

14.

Jiang B, Chen W, Qin H, Diao W, Li B, Cao W . TOX3 inhibits cancer cell migration and invasion via transcriptional regulation of SNAI1 and SNAI2 in clear cell renal cell carcinoma. Cancer Lett. 2019; 449:76-86. DOI: 10.1016/j.canlet.2019.02.020. View

15.

Xiong Y, Liu L, Bai Q, Xia Y, Qu Y, Wang J . Individualized immune-related gene signature predicts immune status and oncologic outcomes in clear cell renal cell carcinoma patients. Urol Oncol. 2019; 38(1):7.e1-7.e8. DOI: 10.1016/j.urolonc.2019.09.014. View

16.

Rini B, Campbell S, Escudier B . Renal cell carcinoma. Lancet. 2009; 373(9669):1119-32. DOI: 10.1016/S0140-6736(09)60229-4. View

17.

Eun H, Cho S, Lee B, Seong I, Kim K . Profiling cytochrome P450 family 4 gene expression in human hepatocellular carcinoma. Mol Med Rep. 2018; 18(6):4865-4876. PMC: 6236316. DOI: 10.3892/mmr.2018.9526. View

18.

Harrell Jr F, Califf R, Pryor D, Lee K, Rosati R . Evaluating the yield of medical tests. JAMA. 1982; 247(18):2543-6. View

19.

Malouf G, Zhang J, Yuan Y, Comperat E, Roupret M, Cussenot O . Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol. 2014; 9(1):32-43. PMC: 4516270. DOI: 10.1016/j.molonc.2014.07.007. View

20.

Luo Y, Shen D, Chen L, Wang G, Liu X, Qian K . Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma. Aging (Albany NY). 2019; 11(16):6029-6052. PMC: 6738436. DOI: 10.18632/aging.102161. View